Benzinga | Jun 23, 2021 06:08AM EDT

Orphazyme Announced Goldman Sachs Aggregate Holding of Shares and Financial Instruments in the Company Increased to 5.8% as of June 16, 2021 and was Reduced to Less than 5% as of June 17, 2021

Orphazyme A/S (NASDAQ:ORPH) ("the Company"), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notifications pursuant to Section 38 of the Danish Capital Markets Act from The Goldman Sachs Group, Inc., that as of June 16, 2021, The Goldman Sachs Group, Inc.'s aggregate holding of shares and financial instruments increased to 5.58% of the share capital and voting rights in the Company, and as of June 17, 2021, The Goldman Sachs Group, Inc.'s aggregate holding of shares and financial instruments has been reduced to less than 5% of the shares and voting rights in the Company.